10 Things to Know for Thursday

FILE – In this May 2016 file photo provided by Kite Pharma, cell therapy specialists at the company’s manufacturing facility in El Segundo, Calif., prepare blood cells from a patient to be engineered in the lab to fight cancer. On Wednesday, Oct. 18, 2017, the Food and Drug Administration approved sales of the therapy Yescarta, developed by Kite Pharma. It is the second gene therapy for U.S. patients _ the first one for adults _ a custom-made, one-time treatment for certain common types of the blood cancer lymphoma. (Kite Pharma via AP, File)

Click here and log in to view this story

Start Free AccountGet access to 7 premium stories every month for FREE!

Already a Subscriber?Current print subscriber? Activate your complimentary Digital account.

Subscribe NowChoose a package that suits your preferences.

US regulators approve 2nd gene therapy for blood cancer

China's economic growth rate slips to 6.8 percent in quarter ending in September from previous quarter's 6.9 percent

Share this story

0 Comments

Cancel reply

Your email address will not be published. Required fields are marked *

Name *

Email *

By participating in online discussions you acknowledge that you have agreed to the TERMS OF SERVICE. An insightful discussion of ideas and viewpoints is encouraged, but comments must be civil and in good taste, with no personal attacks. If your comments are inappropriate, you may be banned from posting. To report comments that you believe do not follow our guidelines, send us an email.

For security purposes, check this box before commenting